FDA clears chemical warfare protectant
Executive Summary
U.S. Army Medical Research and Materiel Command NDA (21-084) for Skin Exposure Reduction Paste Against Chemical Warfare Agents is approved by the Dermatologic & Dental Drug Products Division Feb. 17. SERPACWA received a "1P" new chemical entity priority review from the agency. It is approved for use in conjunction with Mission Oriented Protective Posture gear to reduce or delay the absorption of chemical warfare agents through the skin when applied prior to exposure